Brolucizumab for Wet Age-Related Macular Degeneration in Switch Patients: Long-Term Real-World Experience from a Tertiary Center.

INTRODUCTION

This retrospective, single-center, observational cohort study evaluated the 3-year real-world efficacy and safety of intravitreal brolucizumab injections in patients with neovascular age-related macular degeneration (nAMD) who had previously been treated with other anti-vascular endothelial growth factor (VEGF) agents. A total of 97 eyes from 91 patients were included, all of whom completed 3 years of follow-up after switching to brolucizumab.

METHODS

Patients received intravitreal injections of 6 mg brolucizumab. Data on best-corrected visual acuity (BCVA), central subfield thickness (CST), intraretinal fluid (IRF), subretinal fluid (SRF), subretinal pigment epithelium fluid (sRPEF), treatment intervals, and adverse events were collected over a 3-year follow-up period.

RESULTS

The mean age of patients was 78.9 ± 8.2 years, with a mean follow-up of 161.3 weeks. At 3-year follow-up, mean BCVA significantly improved, from 41.1 ± 6.5 at baseline to 50.7 ± 7.5 ETDRS letters (p < 0.001), and mean CST significantly decreased from 371.3 ± 136.7 to 299.1 ± 137.81 (p < 0.001). Significant reductions were observed in IRF (p < 0.001), SRF (p < 0.001), and sRPEF (p = 0.004). Mean injections per year were 4.7 ± 1.9, 3.9 ± 1.7, and 3.6 ± 1.9 in the first, second, and third years, respectively. Adverse events were noted in 4 patients after either the first or second injection, with no further events reported.

CONCLUSION

This study reports that brolucizumab provides favorable anatomical and functional outcomes and can reduce treatment burden in patients with nAMD due to its rapid and sustained efficacy and favorable safety profile.